- Home
- ERAS vs UPST Comparison
ERAS vs UPST Comparison
Compare ERAS & UPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | UPST |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ERAS | UPST |
|---|---|---|
| Price | $12.64 | $30.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $14.25 | ★ $45.84 |
| AVG Volume (30 Days) | ★ 7.0M | 4.5M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.23 | ★ 131.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,043,857,000.00 |
| Revenue This Year | N/A | $34.45 |
| Revenue Next Year | N/A | $32.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 63.99 |
| 52 Week Low | $1.12 | $23.97 |
| 52 Week High | $24.28 | $85.31 |
Technical Indicators
Market Signals| Indicator | ERAS | UPST |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 52.62 |
| Support Level | $1.76 | $25.18 |
| Resistance Level | $16.14 | $30.67 |
| Average True Range (ATR) | 0.71 | 1.71 |
| MACD | 0.38 | 0.08 |
| Stochastic Oscillator | 91.53 | 78.53 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.